RadNet Stock Forecast, Price & News

-1.51 (-4.19 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume271,620 shs
Average Volume211,160 shs
Market Capitalization$1.82 billion
P/E Ratio172.45
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RadNet and its competitors with MarketBeat's FREE daily newsletter.

RadNet logo

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

547th out of 2,102 stocks

Medical Laboratories Industry

11th out of 40 stocks

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

RadNet (NASDAQ:RDNT) Frequently Asked Questions

Is RadNet a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RadNet stock.
View analyst ratings for RadNet
or view top-rated stocks.

What stocks does MarketBeat like better than RadNet?

Wall Street analysts have given RadNet a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but RadNet wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for RadNet

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) issued its quarterly earnings results on Monday, May, 10th. The medical research company reported $0.04 EPS for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.08. The medical research company earned $315.30 million during the quarter, compared to the consensus estimate of $283.07 million. RadNet had a net margin of 0.99% and a trailing twelve-month return on equity of 4.80%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same period last year, the firm posted ($0.33) earnings per share.
View RadNet's earnings history

How has RadNet's stock price been impacted by Coronavirus (COVID-19)?

RadNet's stock was trading at $17.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDNT shares have increased by 100.3% and is now trading at $34.49.
View which stocks have been most impacted by COVID-19

What guidance has RadNet issued on next quarter's earnings?

RadNet updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $1.28 billion-1.33 billion, compared to the consensus revenue estimate of $1.27 billion.

What price target have analysts set for RDNT?

2 equities research analysts have issued 1 year price targets for RadNet's stock. Their forecasts range from $26.00 to $40.00. On average, they anticipate RadNet's stock price to reach $33.00 in the next year. This suggests that the stock has a possible downside of 4.3%.
View analysts' price targets for RadNet
or view top-rated stocks among Wall Street analysts.

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger, Chairman, Pres & CEO (Age 75, Pay $1.91M)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 50, Pay $739.18k)
  • Mr. Norman R. Hames, Pres & COO of Western Operations (Age 65, Pay $803.5k)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 60, Pay $814.56k)
  • Mr. Ranjan Jayanathan, Exec. VP, Chief Information Officer & GM of eRAD - Radiology Information Technology Division (Age 65)
  • Mr. Mital Patel, Exec. VP of Financial Planning & Analysis and Chief Admin. Officer (Age 35)
  • Ms. Laura Foster BSRT, MPH, J.D., Sr. VP of Compliance & Regulatory Affairs
  • Mr. David Jeffrey Katz, Exec. VP, Gen. Counsel & Corp. Sec. (Age 57)
  • Ms. Ruth Louisa Wilson, Sr. VP of HR & Director (Age 57)
  • Dr. John V. Crues III, VP, Medical Director & Director (Age 71)

What is Howard G. Berger's approval rating as RadNet's CEO?

174 employees have rated RadNet CEO Howard G. Berger on Howard G. Berger has an approval rating of 45% among RadNet's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), The Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.51%), Beck Mack & Oliver LLC (3.95%), Dimensional Fund Advisors LP (2.85%), Renaissance Technologies LLC (2.50%), Global Alpha Capital Management Ltd. (1.71%) and Geode Capital Management LLC (1.36%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, John V Crues, Lawrence L Levitt, Mark Stolper, Michael L Md Sherman, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends for RadNet

Which major investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Renaissance Technologies LLC, Putnam Investments LLC, Dimensional Fund Advisors LP, Millennium Management LLC, Global Alpha Capital Management Ltd., BNP Paribas Arbitrage SA, and Cubist Systematic Strategies LLC. Company insiders that have sold RadNet company stock in the last year include John V Crues, Lawrence L Levitt, Michael N Murdock, Norman R Hames, and Ruth Louisa Villigerwilson.
View insider buying and selling activity for RadNet
or view top insider-selling stocks.

Which major investors are buying RadNet stock?

RDNT stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Russell Investments Group Ltd., Arrowstreet Capital Limited Partnership, Pacer Advisors Inc., Geode Capital Management LLC, Advantage Alpha Capital Partners LP, and Beck Mack & Oliver LLC. Company insiders that have bought RadNet stock in the last two years include B Kaplan Survivor's Tru Karen, and Lawrence L Levitt.
View insider buying and selling activity for RadNet
or or view top insider-buying stocks.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $34.49.

How much money does RadNet make?

RadNet has a market capitalization of $1.82 billion and generates $1.07 billion in revenue each year. The medical research company earns $-14,840,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does RadNet have?

RadNet employs 8,327 workers across the globe.

What is RadNet's official website?

The official website for RadNet is

Where are RadNet's headquarters?

RadNet is headquartered at 1510 COTNER AVE, LOS ANGELES CA, 90025.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at (310) 478-7808 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.